<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Exploration – Hypothesis Development Award**<br>Go to:  
* Program Announcement  
* General Application Instructions<br>Grants.gov Funding Opportunity Number: W81XWH-15-TSCRP-EHDA | Investigators at all academic levels (or equivalent), or postdoctoral fellows | - Supports the initial exploration of innovative, high-risk, high-gain concepts in TSC research to lay the groundwork for future avenues of investigation.  
- *Preliminary or published data encouraged but not required.*  
- Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.  
- Clinical trials not allowed. | - The maximum period of performance is 2 years.  
- The maximum allowable funding for the entire period of performance is $150,000 in direct costs.  
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-application (Letter of Intent):  
July 10, 2015  
5:00 p.m. Eastern time (ET)<br>Application:  
July 27, 2015  
11:59 p.m. ET |
| **Idea Development Award**<br>Go to:  
* Program Announcement  
* General Application Instructions<br>Grants.gov Funding Opportunity Number: W81XWH-15-TSCRP-IDA | Principal Investigator: Must be an independent investigator with a documented faculty appointment (or equivalent).  
Optional Qualified Collaborator: Must be at or above the level of Assistant Professor (or equivalent) and meets at least 10% level of effort on the proposed research project. | - Supports conceptually innovative, high-risk, and potentially high-reward research in the early stages of development that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care.  
- *Preliminary or published data required.*  
- **Optional Features:** Applications that include a Qualified Collaborator who meets criteria identified in the Program Announcement/Funding Opportunity may apply for a higher level of funding.  
- Clinical trials not allowed. | - The maximum period of performance is 3 years.  
- The maximum allowable funding for the entire period of performance is $450,000 in direct costs ($600,000 in direct costs if requesting an Optional Qualified Collaborator).  
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. | Pre-application (Letter of Intent):  
July 10, 2015  
5:00 p.m. ET<br>Application:  
July 27, 2015  
11:59 p.m. ET |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pilot Clinical Trial Award</td>
<td></td>
<td>- Supports exploratory studies that produce diagnostic or therapeutic information, safety, and tolerability studies and studies to determine the mechanism of action.</td>
<td>- The maximum period of performance is 2 years.</td>
<td>Pre-application (Letter of Intent): July 10, 2015 5:00 p.m. ET</td>
</tr>
<tr>
<td>Go to:</td>
<td></td>
<td>- Should be aimed at obtaining preliminary data leading to the development of interventions, as well as clinical biomarkers.</td>
<td>- The maximum allowable funding for the entire period of performance is $300,000 in direct costs.</td>
<td>Application: July 27, 2015 11:59 p.m. ET</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- <strong>Scientific rationale and preliminary data required.</strong></td>
<td>- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</td>
<td></td>
</tr>
<tr>
<td>Grants.gov Funding</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opportunity Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W81XWH-15-TSCRP-PCTA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Eligibility:**
- Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
- Should be aimed at obtaining preliminary data leading to the development of interventions, as well as clinical biomarkers.
- **Scientific rationale and preliminary data required.**

**Funding:**
- The maximum period of performance is 2 years.
- The maximum allowable funding for the entire period of performance is $300,000 in direct costs.
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.